{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T11:39:27Z","timestamp":1777894767535,"version":"3.51.4"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T00:00:00Z","timestamp":1643414400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004320","name":"Philips","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ygyno.2022.01.027","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T10:35:41Z","timestamp":1643798141000},"page":"114-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium"],"prefix":"10.1016","volume":"165","author":[{"given":"Phyllis","family":"van der Ploeg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aniek","family":"Uittenboogaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven L.","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"van Diest","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yvonne J.W.","family":"Wesseling-Rozendaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"van de Stolpe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrina","family":"Lambrechts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruud L.M.","family":"Bekkers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jurgen M.J.","family":"Piek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 2","key":"10.1016\/j.ygyno.2022.01.027_bb0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ijgo.12614","article-title":"Cancer of the ovary, fallopian tube, and peritoneum","volume":"143","author":"Berek","year":"2018","journal-title":"Int. J. Gynaecol. Obstet."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0010","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/030089160909500212","article-title":"Factors related to recurrence after pathological complete response to postoperative chemotherapy in patients with epithelial ovarian cancer","volume":"95","author":"Karagol","year":"2009","journal-title":"Tumori."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.ygyno.2020.01.010","article-title":"Minimal residual disease at primary debulking surgery versus complete tumor resection at interval debulking surgery in advanced epithelial ovarian cancer: A survival analysis","volume":"157","author":"Ghirardi","year":"2020","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0020","doi-asserted-by":"crossref","DOI":"10.3390\/cancers10110433","article-title":"Cell origins of high-grade serous ovarian Cancer","volume":"10","author":"Kim","year":"2018","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0025","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1002\/path.1000","article-title":"Dysplastic changes in prophylactically removed fallopian tubes of women predisposed to developing ovarian cancer","volume":"195","author":"Piek","year":"2001","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1046\/j.1365-2559.2003.01654.x","article-title":"Expression of differentiation and proliferation related proteins in epithelium of prophylactically removed ovaries from women with a hereditary female adnexal cancer predisposition","volume":"43","author":"Piek","year":"2003","journal-title":"Histopathology."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0035","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/01.pas.0000213335.40358.47","article-title":"Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship","volume":"31","author":"Kindelberger","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0040","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/path.3023","article-title":"TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma--evidence supporting the clonal relationship of the two lesions","volume":"226","author":"Kuhn","year":"2012","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0045","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.ccr.2013.10.013","article-title":"Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models","volume":"24","author":"Perets","year":"2013","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ygyno.2022.01.027_bb0050","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/path.4649","article-title":"In vitro and in vivo correlates of physiological and neoplastic human fallopian tube stem cells","volume":"238","author":"Yamamoto","year":"2016","journal-title":"J. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0055","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1158\/2159-8290.CD-16-0607","article-title":"Genomics of ovarian Cancer progression reveals diverse metastatic trajectories including intraepithelial metastasis to the fallopian tube","volume":"6","author":"Eckert","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0060","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1038\/s41467-017-01217-9","article-title":"Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma","volume":"8","author":"Ducie","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0065","doi-asserted-by":"crossref","first-page":"4424","DOI":"10.1038\/onc.2013.394","article-title":"FOXO3a loss is a frequent early event in high-grade pelvic serous carcinogenesis","volume":"33","author":"Levanon","year":"2014","journal-title":"Oncogene."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0070","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.semcancer.2017.11.017","article-title":"Re-evaluating the role of FOXOs in cancer","volume":"50","author":"Hornsveld","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0075","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1007\/s12032-012-0275-z","article-title":"The expression and prognosis of FOXO3a and Skp2 in human ovarian cancer","volume":"29","author":"Lu","year":"2012","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0080","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1080\/07357900802146204","article-title":"Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients","volume":"27","author":"Fei","year":"2009","journal-title":"Cancer Investig."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12092660","article-title":"Signal transduction pathway activity in high-grade, serous ovarian carcinoma reveals a more favorable prognosis in tumors with low PI3K and high NF-kappaB pathway activity: A novel approach to a long-standing enigma","volume":"12","author":"van Lieshout","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0090","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.ajpath.2018.05.020","article-title":"Assessment of functional phosphatidylinositol 3-kinase pathway activity in cancer tissue using Forkhead box-O target gene expression in a knowledge-based computational model","volume":"188","author":"van Ooijen","year":"2018","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0095","doi-asserted-by":"crossref","first-page":"2936","DOI":"10.1158\/0008-5472.CAN-13-2515","article-title":"Selection of personalized patient therapy through the use of knowledge-based computational models that identify tumor-driving signal transduction pathways","volume":"74","author":"Verhaegh","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0100","article-title":"RNA based approaches to profile oncogenic pathways from low quantity samples to drive precision oncology strategies","volume":"11","author":"van de Stolpe","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0105","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1038\/s41598-018-38179-x","article-title":"Enabling precision medicine by unravelling disease pathophysiology: quantifying signal transduction pathway activity across cell and tissue types","volume":"9","author":"van de Stolpe","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0110","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11030293","article-title":"Quantitative measurement of functional activity of the PI3K signaling pathway in Cancer","volume":"11","author":"van de Stolpe","year":"2019","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41416-020-0925-4","article-title":"Oestrogen receptor pathway activity is associated with outcome in endometrial cancer","volume":"123","author":"van Weelden","year":"2020","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2022.01.027_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cells8020176","article-title":"The role of androgen receptor signaling in ovarian cancer","volume":"8","author":"Mizushima","year":"2019","journal-title":"Cells."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061647","article-title":"Estrogen signaling and its potential as a target for therapy in ovarian cancer","volume":"12","author":"Langdon","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.semcancer.2019.05.012","article-title":"Role of the PI3K\/AKT\/mTOR signaling pathway in ovarian cancer: biological and therapeutic significance","volume":"59","author":"Ediriweera","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0135","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/ijms14011179","article-title":"Hedgehog signaling pathway in ovarian cancer","volume":"14","author":"Szkandera","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11050668","article-title":"Review: targeting the transforming growth factor-beta pathway in ovarian cancer","volume":"11","author":"Roane","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ygyno.2022.01.027_bb0145","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8101658","article-title":"Wnt signaling in ovarian cancer stemness, EMT, and therapy resistance","volume":"8","author":"Teeuwssen","year":"2019","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0150","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/PGP.0b013e31824cbeb4","article-title":"Ki-67 labeling index as an adjunct in the diagnosis of serous tubal intraepithelial carcinoma","volume":"31","author":"Kuhn","year":"2012","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0155","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/0366-6999.198932","article-title":"Expression of PH domain leucine-rich repeat protein phosphatase, Forkhead Homeobox type O 3a and RAD51, and their relationships with Clinicopathologic features and prognosis in ovarian serous adenocarcinoma","volume":"130","author":"Zhang","year":"2017","journal-title":"Chin. Med. J."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0160","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","article-title":"Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor","volume":"96","author":"Brunet","year":"1999","journal-title":"Cell."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0165","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ygyno.2011.05.021","article-title":"Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas","volume":"123","author":"Karst","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0170","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ygyno.2015.07.100","article-title":"Stathmin 1 and p16(INK4A) are sensitive adjunct biomarkers for serous tubal intraepithelial carcinoma","volume":"139","author":"Novak","year":"2015","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0175","doi-asserted-by":"crossref","first-page":"12642","DOI":"10.1038\/srep12642","article-title":"Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin beta4 and Akt signals","volume":"5","author":"Lee","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0180","article-title":"Cyclic activity of signal transduction pathways in fimbrial epithelium of the human fallopian tube","author":"van der Ploeg","year":"2021","journal-title":"Acta Obstet Gynecol Scand."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0185","doi-asserted-by":"crossref","first-page":"7678","DOI":"10.1158\/0008-5472.CAN-04-2933","article-title":"Mutation of the PIK3CA gene in ovarian and breast cancer","volume":"64","author":"Campbell","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024433","article-title":"High throughput interrogation of somatic mutations in high grade serous cancer of the ovary","volume":"6","author":"Matulonis","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ygyno.2022.01.027_bb0195","doi-asserted-by":"crossref","first-page":"779","DOI":"10.4161\/cbt.5.7.2751","article-title":"Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms","volume":"5","author":"Nakayama","year":"2006","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0200","doi-asserted-by":"crossref","first-page":"4","DOI":"10.5732\/cjc.014.10289","article-title":"The PI3K\/Akt\/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges","volume":"34","author":"Cheaib","year":"2015","journal-title":"Chin. J. Cancer."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0205","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","author":"Cancer Genome Atlas Research N","year":"2011","journal-title":"Nature."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0210","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1073\/pnas.1421839112","article-title":"Only three driver gene mutations are required for the development of lung and colorectal cancers","volume":"112","author":"Tomasetti","year":"2015","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0215","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(14)61687-1","article-title":"Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies","volume":"385","author":"Beral","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.ygyno.2022.01.027_bb0220","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.4081\/ejh.2014.2251","article-title":"Morphological and immunohistochemical study of ovarian and tubal dysplasia associated with tamoxifen","volume":"58","author":"Chene","year":"2014","journal-title":"Eur. J. Histochem."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0225","first-page":"237","article-title":"Efficacy of anti-hormonal therapy in estrogen receptor positive high-grade serous ovarian carcinoma: a systematic review","volume":"4","author":"van der Ploeg","year":"2020","journal-title":"J. Cancer Sci. Clin. Therap."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0230","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/onc.2009.392","article-title":"Activation of the hedgehog-signaling pathway in human cancer and the clinical implications","volume":"29","author":"Yang","year":"2010","journal-title":"Oncogene."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0235","doi-asserted-by":"crossref","first-page":"7659","DOI":"10.1158\/1078-0432.CCR-08-1414","article-title":"Role of hedgehog signaling in ovarian cancer","volume":"14","author":"Bhattacharya","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0240","doi-asserted-by":"crossref","first-page":"4838","DOI":"10.1073\/pnas.0712216105","article-title":"Hedgehog signaling overrides p53-mediated tumor suppression by activating Mdm2","volume":"105","author":"Abe","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0245","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/emboj.2009.16","article-title":"A GLI1-p53 inhibitory loop controls neural stem cell and tumour cell numbers","volume":"28","author":"Stecca","year":"2009","journal-title":"EMBO J."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0250","doi-asserted-by":"crossref","first-page":"833","DOI":"10.18632\/oncotarget.13662","article-title":"DYRK1B blocks canonical and promotes non-canonical hedgehog signaling through activation of the mTOR\/AKT pathway","volume":"8","author":"Singh","year":"2017","journal-title":"Oncotarget."},{"key":"10.1016\/j.ygyno.2022.01.027_bb0255","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s12032-014-0368-y","article-title":"Sonic hedgehog-Gli1 signals promote epithelial-mesenchymal transition in ovarian cancer by mediating PI3K\/AKT pathway","volume":"32","author":"Ke","year":"2015","journal-title":"Med. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582200066X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582200066X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:58:15Z","timestamp":1758772695000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582200066X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S009082582200066X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.027","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Signal transduction pathway activity in high-grade serous carcinoma, its precursors and Fallopian tube epithelium","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2022.01.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}